User login
Key clinical point: Deucravacitinib improved patient-reported outcomes (PRO) for physical and social functioning, mental health, fatigue, and pain in patients with active psoriatic arthritis (PsA).
Major finding: At week 16, 6 mg deucravacitinib vs placebo led to significant changes in functional ability as assessed by the Health Assessment Questionnaire-Disability Index (−0.26; 95% CI −0.42 to −0.10) and the 36-Item Short-Form Health Survey physical component summary (3.3; 95% CI 0.9 to 5.7), with similar outcomes for 12 mg deucravacitinib. Improvements were also noted in mental health and quality of life at week 16 with deucravacitinib vs placebo.
Study details: Findings are from a phase 2, double-blind trial that included 203 patients with active PsA who were randomly assigned (1:1:1) to receive 6 mg deucravacitinib daily (n = 70), 12 mg deucravacitinib daily (n = 67), or placebo (n = 66) for 16 weeks.
Disclosures: This study was sponsored by Bristol Myers Squibb. The authors declared no conflicts of interest.
Source: Strand V, Gossec L, Coates LC, et al. Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized phase 2 trial. Arthritis Care Res (Hoboken). 2024 (Mar 26). doi: 10.1002/acr.25333 Source
Key clinical point: Deucravacitinib improved patient-reported outcomes (PRO) for physical and social functioning, mental health, fatigue, and pain in patients with active psoriatic arthritis (PsA).
Major finding: At week 16, 6 mg deucravacitinib vs placebo led to significant changes in functional ability as assessed by the Health Assessment Questionnaire-Disability Index (−0.26; 95% CI −0.42 to −0.10) and the 36-Item Short-Form Health Survey physical component summary (3.3; 95% CI 0.9 to 5.7), with similar outcomes for 12 mg deucravacitinib. Improvements were also noted in mental health and quality of life at week 16 with deucravacitinib vs placebo.
Study details: Findings are from a phase 2, double-blind trial that included 203 patients with active PsA who were randomly assigned (1:1:1) to receive 6 mg deucravacitinib daily (n = 70), 12 mg deucravacitinib daily (n = 67), or placebo (n = 66) for 16 weeks.
Disclosures: This study was sponsored by Bristol Myers Squibb. The authors declared no conflicts of interest.
Source: Strand V, Gossec L, Coates LC, et al. Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized phase 2 trial. Arthritis Care Res (Hoboken). 2024 (Mar 26). doi: 10.1002/acr.25333 Source
Key clinical point: Deucravacitinib improved patient-reported outcomes (PRO) for physical and social functioning, mental health, fatigue, and pain in patients with active psoriatic arthritis (PsA).
Major finding: At week 16, 6 mg deucravacitinib vs placebo led to significant changes in functional ability as assessed by the Health Assessment Questionnaire-Disability Index (−0.26; 95% CI −0.42 to −0.10) and the 36-Item Short-Form Health Survey physical component summary (3.3; 95% CI 0.9 to 5.7), with similar outcomes for 12 mg deucravacitinib. Improvements were also noted in mental health and quality of life at week 16 with deucravacitinib vs placebo.
Study details: Findings are from a phase 2, double-blind trial that included 203 patients with active PsA who were randomly assigned (1:1:1) to receive 6 mg deucravacitinib daily (n = 70), 12 mg deucravacitinib daily (n = 67), or placebo (n = 66) for 16 weeks.
Disclosures: This study was sponsored by Bristol Myers Squibb. The authors declared no conflicts of interest.
Source: Strand V, Gossec L, Coates LC, et al. Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized phase 2 trial. Arthritis Care Res (Hoboken). 2024 (Mar 26). doi: 10.1002/acr.25333 Source